Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma

References

• Subramaniam MM, Chan JY, Yeoh KG, et al. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta. 2009;1796:315–331.
   PubMed Web of Science ®Google Scholar
• Volkel P, Dupret B, Le Bourhis X, et al. Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res. 2015;7:175–193.
   PubMed Web of Science ®Google Scholar
• Fujii S, Ito K, Ito Y, et al. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem. 2008;283:17324–17332.
   PubMed Web of Science ®Google Scholar
• Wang C, Liu Z, Woo CW, et al. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res. 2012;72:315–324.
   PubMed Web of Science ®Google Scholar
• Tang B, Du J, Li Y, et al. EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3. Med Oncol. 2014;31:271.
   PubMed Web of Science ®Google Scholar
• Kodach LL, Jacobs RJ, Heijmans J, et al. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis. 2010;31:1567–1575.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kim EJ, Jeong P, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 2005;65:9347–9354.
   PubMed Web of Science ®Google Scholar
• Berg M, Nordgaard O, Korner H, et al. Molecular subtypes in stage II-III colon cancer defined by genomic instability: early recurrence-risk associated with a high copy-number variation and loss of RUNX3 and CDKN2A. PLoS One. 2015;10:e0122391.
   Web of Science ®Google Scholar
• Lau QC, Raja E, Salto-Tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006;66:6512–6520.
   PubMed Web of Science ®Google Scholar
• Wang CQ, Krishnan V, Tay LS, et al. Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects. Cell Rep. 2014;8:767–782.
   PubMed Web of Science ®Google Scholar
• Estecio MR, Maddipoti S, Bueso-Ramos C, et al. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol. 2015;169:344–351.
   PubMed Web of Science ®Google Scholar
• Damdinsuren A, Matsushita H, Ito M, et al. FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3. Leuk Res. 2015;39:1405–1413.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251–262.
   PubMed Web of Science ®Google Scholar
• O'Malley DP, Auerbach A, Weiss LM. Practical applications in immunohistochemistry: evaluation of diffuse large B-cell lymphoma and related large B-cell lymphomas. Arch Pathol Lab Med. 2015;139:1094–1107.
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181–185.
   PubMed Web of Science ®Google Scholar
• WHO classification of tumours of haematopoietic and lymphoid tissues. Swerdlow SH, Campo E, Harris NL, et al., editors. Lyon, France: World Health Organization International Agency for Research on Cancer; 2008. 439 p.
   Google Scholar
• Hidalgo A, Pina P, Guerrero G, et al. A simple method for the construction of small format tissue arrays. J Clin Pathol. 2003;56:144–146.
   PubMed Web of Science ®Google Scholar
• Wang L, Wei D, Huang S, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–6380.
   PubMed Web of Science ®Google Scholar
• Merola E, Mattioli E, Minimo C, et al. Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus. J Cell Physiol. 2006;207:512–519.
   PubMed Web of Science ®Google Scholar
• Lee CW, Chuang LS, Kimura S, et al. RUNX3 functions as an oncogene in ovarian cancer. Gynecol Oncol. 2011;122:410–417.
   PubMed Web of Science ®Google Scholar
• Salto-Tellez M, Peh BK, Ito K, et al. RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene. 2006;25:7646–7649.
   PubMed Web of Science ®Google Scholar
• Tsunematsu T, Kudo Y, Iizuka S, et al. RUNX3 has an oncogenic role in head and neck cancer. PLoS One. 2009;4:e5892.
   PubMed Web of Science ®Google Scholar
• Lotem J, Levanon D, Negreanu V, et al. Runx3 at the interface of immunity, inflammation and cancer. Biochim Biophys Acta. 2015;1855:131–143.
   PubMed Web of Science ®Google Scholar
• Hopp L, Loffler-Wirth H, Binder H. Epigenetic heterogeneity of B-cell lymphoma: DNA methylation, gene expression and chromatin states. Genes. 2015;6:812–840.
   PubMed Web of Science ®Google Scholar
• Santos Gda C, Saieg MA, Ko HM, et al. Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation. Cancer Cytopathol. 2015;123:413–420.
   PubMed Web of Science ®Google Scholar
• Caganova M, Carrisi C, Varano G, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest. 2013;123:5009–5022.
   PubMed Web of Science ®Google Scholar
• Xu B, Konze KD, Jin J, et al. Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp Hematol. 2015;43:698–712.
   PubMed Web of Science ®Google Scholar
• Campbell JE, Kuntz KW, Knutson SK, et al. EPZ011989, a potent, orally-available EZH2 inhibitor with robust in vivo activity. ACS Med Chem Lett. 2015;6:491–495.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Gao J, Popovic R, et al. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma. 2015;56:2895–2901.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Kwong YL, et al. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol. 2014;93:1263–1277.
   PubMed Web of Science ®Google Scholar
• Cabanillas F. Non-Hodgkin's lymphoma: the old and the new. Clin Lymphoma Myeloma Leuk. 2011;11:S87–S90.
   PubMedGoogle Scholar
• Lunning MA, Green MR. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J. 2015;5:e361.
   PubMed Web of Science ®Google Scholar
• Kreisel F, Kulkarni S, Kerns RT, et al. High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy. Cancer Genet. 2011;204:129–137.
   PubMed Web of Science ®Google Scholar